256375-13-0

Upstream product

• 747397-02-0 3-[(3S,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidin-3-yl]-propionic acid 
• 256375-11-8 (E)-3-[(3S,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidin-3-yl]-acrylic acid methyl ester 
• 214335-16-7 (-)-Methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3β-carboxylate 
• 214335-31-6 (3S,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidine-3-carbaldehyde 
• 214335-19-0 (3S,4S)-4-(4-chlorophenyl)-3-(hydroxymethyl)-1-methylpiperidine 

Downstream Products

• 256375-14-1 2-{{3-[(3S,4S)-4-(4-Chloro-phenyl)-1-methyl-piperidin-3-yl]-propyl}-[2-(4-methoxy-benzylsulfanyl)-ethyl]-amino}-N-[2-(4-methoxy-benzylsulfanyl)-ethyl]-acetamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of two novel DAT-binding technetium complexes containing a piperidine based analogue of cocaine

Two new technetium complexes containing a piperidine template have been synthesized and evaluated as possible leads for the development of dopamine transporter (DAT) imaging agents. Binding data for the corresponding rhenium complexes containing either a monoaminomonoamide (MAMA') or a diaminodithiol (DADT) chelating unit exhibited significant affinity for the DAT. Initial biodistribution studies in rats revealed only a low brain uptake.